Dark Matter Blog

Author Archive

Want A Great Team? Pick Great Leaders.

July 19th, 2021
by Jennifer Petter, PhD
Founder and CSO, Arrakis

Back in 2015, I felt compelled to set out in a new direction in drug discovery. I was in my third year as VP of Chemistry for Celgene. This was a great gig – good people, good science. However, it required a level of travel that began to seem excessive. My kids were old enough […]

A new drug approval for the vanguard of RNA-targeted small molecules

August 27th, 2020
by Jennifer Petter, PhD
Founder and CSO, Arrakis

A few years ago, at Arrakis Therapeutics, we set out to conquer a strange new territory, drugging RNA structures with small molecules. We have overcome many obstacles on this mission, inventing new concepts and methods where necessary and re-engineering known concepts and methods where possible. But we have not been the only people on this […]

The Rime of the Ancient Medicinal Chemist: Structure, Structure Everywhere

April 20th, 2018
by Jennifer Petter, PhD
Founder and CSO, Arrakis

Our mission at Arrakis is to find small-molecule drugs that bind RNA, or RNA-targeted Small Molecules (rSMs). One of the articles of faith that informs and motivates this mission is that non-ribosomal RNA folds into structures that present small-molecule-compatible pockets and that those structures mediate important biological events. And, just as importantly, that binding of […]

Why NOW for Targeting RNA with Small Molecules?

November 28th, 2017
by Jennifer Petter, PhD
Founder and CSO, Arrakis

In “The Right Stuff,” Tom Wolfe noted that astronauts were granted hero status before their missions, perhaps because no one expected them to return. Happily, Arrakis also has received a lot of laudatory attention just for launching the mission of drugging RNAs with small molecules – before we’ve even achieved it. The plaudits are lovely, […]

Back to Top